Skip to main content
915 TLDR
Health
1 read

Viral Treatment for Menopause Symptoms Raises Safety Concerns Among Experts

KVIA••CNN Newsource
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

Read Original

AI Summary

A viral trend suggests that a combination of over-the-counter medications, specifically an antihistamine and an acid reducer, can alleviate symptoms of perimenopause and menopause. While anecdotal reports online claim improvements in symptoms like hot flashes and skin sensitivity, medical experts caution that these medications have not been approved by the FDA for such use. The average age for menopause in the U.S. is around 52, and symptoms can significantly impact daily life. Women considering this treatment are advised to consult their primary care physician due to potential side effects and interactions with other medications.

Key Details: • Consult your doctor before trying this combination of medications. • Symptoms targeted include hot flashes, night sweats, and facial flushing. • The average age for menopause onset in the U.S. is approximately 52 years. • Potential side effects include drowsiness and gastrointestinal issues.

health medications wellness womens-health menopause

People & Organizations

FDACNNLeana Wen

Related Articles

KTSM•Jun 21

New Research Links Hearing Loss to Increased Alzheimer's Risk

As the population ages, the number of individuals diagnosed with Alzheimer's disease is projected to double by 2060, highlighting the urgent need for early detection and intervention. Recent studies suggest that hearing loss may be a significant warning sign of cognitive decline, prompting researchers to explore its implications for Alzheimer's risk. Understanding these connections could lead to better preventative strategies for those at risk. This research is crucial for healthcare providers and families in El Paso and beyond, as it emphasizes the importance of addressing hearing health as part of cognitive wellness.

Health
1 min read
El Paso Matters•Jun 21

El Paso Sees Decline in Accidental Deaths and Drug Overdose Trends in 2025

The latest report from the El Paso County Office of the Medical Examiner reveals a significant 32% decrease in accidental deaths from 2023 to 2025, primarily due to reductions in motor vehicle accidents and drug overdoses. Notably, cocaine-related deaths have surged, surpassing fentanyl for the first time since 2019, with 60 deaths attributed to cocaine last year. Cardiovascular disease remains the leading cause of sudden natural deaths, with high diabetes rates contributing to this trend. The report highlights the ongoing public health challenges in El Paso, including mental health issues among youth, as suicide rates remain stable but concerning, particularly among boys aged 11-18. Residents are encouraged to utilize local mental health resources.

Health
1 min read
KTSM•Jun 20

Medicare Initiates Pilot Program for Expanded Access to GLP-1 Medications

Medicare has announced a pilot program aimed at enhancing access to GLP-1 medications, which are commonly used for diabetes and weight management. This program will be operational from July 1, 2026, through December 31, 2027. The initiative is significant as it seeks to address the growing need for effective treatments in managing chronic conditions, potentially benefiting numerous patients. Stakeholders in the healthcare community should prepare for the changes and consider how this may affect patient care and medication availability.

Health
1 min read
KTSM•Jun 20

Medicare's New Pilot Program to Enhance Access to GLP-1 Medications

Medicare has announced a pilot program aimed at increasing access to GLP-1 medications, which are commonly used for diabetes and weight management. This demonstration will commence on July 1, 2026, and continue until December 31, 2027. The initiative is significant as it addresses the growing demand for these treatments, potentially benefiting many patients who struggle to afford them. Residents should be aware of this upcoming program, as it could impact their healthcare options and costs related to GLP-1 drugs.

Health
1 min read